XORTX Therapeutics Inc. Deferred Tax Expense Income Recognised In Profit Or Loss
XORTX Therapeutics Inc. (XRTX) reported Deferred Tax Expense Income Recognised In Profit Or Loss of CAD 6.12 million for the 12-month period ending 2021-12-31, per its 20-F filed 2022-05-03.
Discontinued › Operating Expenses
ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss · last filed 2022-05-03
| Period end | Deferred Tax Expense Income Recognised In Profit Or Loss 12 month |
|---|---|
| 2021-12-31 | 6.12M CAD 20-F · filed 2022-05-03 |